Advances in medical science have significantly expanded the possibilities for treating several serious diseases, including cancer. Highly effective modern approaches, such as new medicines, targeted therapies and immunotherapy, have brought renewed hope in the treatment of many types of cancer. However, the impact of cancer is not limited to a patient’s health alone. It also affects the emotional, social and financial well-being of the patient’s family. It is equally true that the prolonged course of treatment, frequent hospital visits and high cost of medicines present numerous challenges. These difficulties can sometimes cause patients and their families to lose hope even before they have had the opportunity to begin the fight against the disease.
Patients to receive direct relief
Several factors are responsible for the high cost of cancer medicines. On the one hand, substantial investments are required for the research, development and manufacture of these medicines, particularly biological drugs and newer treatment options. On the other hand, unfair practices such as excessive trade margins across the supply chain also contribute to making cancer medicines expensive. Together, these factors can place a considerable financial burden on patients and their families, making access to essential treatment difficult.
In this context, the Government of India, in the public interest, has rationalised the trade margins of 137 identified non-scheduled anti-cancer medicines through the Trade Margin Rationalisation (TMR) initiative. The measure covers not only medicines available in the domestic market but also those available globally. Under this initiative, the maximum trade margin on these medicines has been fixed at 30 per cent. This step ensures that both existing and future cancer medicines are covered within the 30 per cent trade margin limit. As a result, the maximum retail prices (MRPs) of more than 1,000 cancer medicines have been reduced by between 20 and 70 per cent. The actual reduction in prices may, however, vary across individual medicines and brands.
It is expected that this measure will not only make cancer treatment more affordable but also give patients greater confidence to begin treatment in time. Many patients who had so far hesitated to take the first step towards cancer treatment because of its high cost can now have greater assurance that treatment will be financially more accessible. Making medicines more affordable is an important step towards ensuring that the cost of treatment does not prevent patients from seeking timely medical care.
Key reasons behind the high cost of cancer medicines
Some modern medicines used in cancer treatment, particularly biological drugs and immunotherapies, are more expensive than conventional chemical medicines. This is largely due to the complex processes involved in their development and manufacture. While ordinary chemical medicines are produced through controlled chemical processes, biological medicines are developed with the help of living cells and biological systems. Their manufacture requires highly advanced laboratories, specialised production facilities, complex technologies and stringent quality standards. These requirements make the production process considerably more demanding and have a direct bearing on the final cost of the medicines.
In addition, extensive research and large-scale clinical trials are required to establish the safety and effectiveness of these medicines. These processes are often more complex and time-consuming than those involved in the development of conventional medicines. All these aspects contribute to the overall cost of cancer drugs. Therefore, while making efforts to bring down the prices of cancer medicines, it is equally important to understand the need to encourage the development of new medical technologies and treatment options, while ensuring that their benefits reach patients. The objective must be to strike a balance between supporting medical innovation and making the resulting treatments affordable and accessible to those who need them.
To make these expensive cancer medicines more accessible to patients, more hospitals will need to become part of the Tata Memorial Hospital’s Cancer Grid. Through this network, discussions and negotiations are helping secure price concessions and make newer treatment options more affordable for patients. In addition, these medicines can be made available to patients at lower costs through bulk procurement under government purchasing systems such as the Central Government Health Scheme (CGHS). Such collective procurement mechanisms can help improve access to newer medicines while reducing the financial burden on individual patients.
Check revised prices on the NPPA website and ‘Pharma Sahi Daam’
It is equally important to ensure that the reduction in medicine prices translates into actual benefits for patients and is clearly reflected in their hospital bills. Both government and private hospitals must ensure that patients are charged according to the revised prices. The revised prices have come into effect from 9 November 2026. Patients can check the applicable prices through the National Pharmaceutical Pricing Authority (NPPA) website and the ‘Pharma Sahi Daam’ mobile application. Since a substantial proportion of anti-cancer medicines is supplied directly to hospitals and medical institutions, these institutions must ensure that patients receive the medicines at the reduced prices from the stipulated date. The revised prices should also be prominently displayed at hospitals and pharmacies so that patients and their families can easily access the relevant information and verify the prices being charged. The government is monitoring the effective implementation of this arrangement at the hospital and pharmacy levels through State Drug Controllers and manufacturers. The situation is also being monitored through complaints and feedback received on the ‘Pharma Sahi Daam’ application. These measures are intended to ensure that the entire benefit of the price reductions reaches patients and that the revised prices are implemented effectively across the supply chain. It is essential that the intended relief is not limited to a reduction announced on paper but is reflected in the actual cost borne by patients when they purchase their medicines or receive treatment at hospitals.
Cancer is a long and difficult battle for both the patient and the patient’s family. For doctors and hospitals, every patient who wins the fight against cancer represents another milestone in their efforts and a testament to the importance of accessible medical care. Imposing a trade margin cap on all categories of cancer medicines will make cancer treatment more affordable and accessible. Through the collective efforts of hospitals, pharmacies and non-governmental organisations, we can move closer to ensuring affordable cancer care for patients and their families. Ultimately, the true measure of any health policy lies in ensuring that advances and innovations in medical science continue, while their benefits reach every patient in need. Financial difficulties must not become an obstacle to treatment or deprive anyone of the opportunity to access the medical care they require.
Courtesy PIB Srinagar
(Smt. Anupriya Patel is the Union Minister of State for Health and Family Welfare and the Union Minister of State for Chemicals and Fertilisers.)


